JP2020529863A5 - - Google Patents

Info

Publication number
JP2020529863A5
JP2020529863A5 JP2020520426A JP2020520426A JP2020529863A5 JP 2020529863 A5 JP2020529863 A5 JP 2020529863A5 JP 2020520426 A JP2020520426 A JP 2020520426A JP 2020520426 A JP2020520426 A JP 2020520426A JP 2020529863 A5 JP2020529863 A5 JP 2020529863A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
variable region
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020520426A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020529863A (ja
JP7222987B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/039152 external-priority patent/WO2019005636A2/en
Publication of JP2020529863A publication Critical patent/JP2020529863A/ja
Publication of JP2020529863A5 publication Critical patent/JP2020529863A5/ja
Priority to JP2023015342A priority Critical patent/JP7464764B2/ja
Application granted granted Critical
Publication of JP7222987B2 publication Critical patent/JP7222987B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020520426A 2017-06-25 2018-06-22 抗ror1抗体とその作製及び使用方法 Active JP7222987B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023015342A JP7464764B2 (ja) 2017-06-25 2023-02-03 抗ror1抗体とその作製及び使用方法

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US201762524554P 2017-06-25 2017-06-25
US201762524557P 2017-06-25 2017-06-25
US201762524558P 2017-06-25 2017-06-25
US62/524,554 2017-06-25
US62/524,558 2017-06-25
US62/524,557 2017-06-25
US201762545603P 2017-08-15 2017-08-15
US62/545,603 2017-08-15
US201762551032P 2017-08-28 2017-08-28
US201762551065P 2017-08-28 2017-08-28
US201762551035P 2017-08-28 2017-08-28
US62/551,035 2017-08-28
US62/551,032 2017-08-28
US62/551,065 2017-08-28
PCT/US2018/039152 WO2019005636A2 (en) 2017-06-25 2018-06-22 ANTI-ROR1 ANTIBODIES AND METHODS OF PREPARATION AND USE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023015342A Division JP7464764B2 (ja) 2017-06-25 2023-02-03 抗ror1抗体とその作製及び使用方法

Publications (3)

Publication Number Publication Date
JP2020529863A JP2020529863A (ja) 2020-10-15
JP2020529863A5 true JP2020529863A5 (enExample) 2022-01-17
JP7222987B2 JP7222987B2 (ja) 2023-02-15

Family

ID=64742585

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020520426A Active JP7222987B2 (ja) 2017-06-25 2018-06-22 抗ror1抗体とその作製及び使用方法
JP2020520428A Active JP7323513B2 (ja) 2017-06-25 2018-06-22 抗4-1bb抗体とその作製及び使用方法
JP2023015342A Active JP7464764B2 (ja) 2017-06-25 2023-02-03 抗ror1抗体とその作製及び使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020520428A Active JP7323513B2 (ja) 2017-06-25 2018-06-22 抗4-1bb抗体とその作製及び使用方法
JP2023015342A Active JP7464764B2 (ja) 2017-06-25 2023-02-03 抗ror1抗体とその作製及び使用方法

Country Status (5)

Country Link
US (2) US11987635B2 (enExample)
EP (2) EP3645741A4 (enExample)
JP (3) JP7222987B2 (enExample)
CN (7) CN116731179A (enExample)
WO (2) WO2019005636A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201710835D0 (en) 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Antibodies
GB201710838D0 (en) 2017-07-05 2017-08-16 Ucl Business Plc Bispecific antibodies
GB201710836D0 (en) 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Car T-Cells
WO2020018964A1 (en) 2018-07-20 2020-01-23 Fred Hutchinson Cancer Research Center Compositions and methods for controlled expression of antigen-specific receptors
JP2023512181A (ja) * 2020-01-30 2023-03-24 オンターナル セラピューティクス,インク. 癌を治療するためのegfr阻害剤とror1阻害剤の組み合わせ
KR20220148209A (ko) * 2020-02-28 2022-11-04 상하이 헨리우스 바이오테크, 인크. 항cd137 작제물 및 그 용도
CN111499746B (zh) * 2020-04-28 2020-11-24 优睿赛思(武汉)生物科技有限公司 一种针对人白介素-2的高亲和力兔单克隆抗体及其应用
EP4188430A4 (en) * 2020-07-28 2024-11-06 The Board Of Regents Of The University Of Texas System Monoclonal antibodies against lilrb1 for diagnostic and therapeutic use
EP4209509A4 (en) * 2020-09-03 2025-03-19 Harbour Biomed (Shanghai) Co., Ltd ROR1-TARGETTING ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, METHOD OF PREPARATION THEREOF AND USE THEREOF
US12144827B2 (en) 2021-02-25 2024-11-19 Lyell Immunopharma, Inc. ROR1 targeting chimeric antigen receptor
CN115433277A (zh) * 2021-06-05 2022-12-06 苏州缔码生物科技有限公司 抗cd38兔重组单克隆抗体的制备及应用
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods
TW202320858A (zh) 2021-07-19 2023-06-01 美商薩諾管理公司 免疫接合物及方法
IL312204A (en) 2021-10-28 2024-06-01 Lyell Immunopharma Inc Methods for culturing cells expressing ror1-binding protein
CN116333139B (zh) * 2021-12-22 2026-02-27 上海复旦张江生物医药股份有限公司 一种抗fda0128抗体、其制备方法和应用
WO2024064952A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells overexpressing c-jun
WO2024064958A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2024077174A1 (en) 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
CN120813375A (zh) 2023-01-30 2025-10-17 凯玛布有限公司 抗体
CN118745226B (zh) * 2023-06-07 2026-02-17 浙江博锐生物制药有限公司 抗ror1抗体及其应用
CN117467004B (zh) * 2023-10-09 2024-06-21 武汉爱博泰克生物科技有限公司 抗人钙网膜蛋白的兔单克隆抗体及其应用
WO2025106600A2 (en) * 2023-11-15 2025-05-22 Systimmune, Inc. Anti-dll3 antibody and method of making and using thereof
CN117624355B (zh) * 2023-11-30 2024-05-14 无锡傲锐东源生物科技有限公司 一种抗人乙酰化tau274兔单克隆抗体及其应用
CN117736330B (zh) * 2024-01-24 2024-05-17 上海沙砾生物科技有限公司 肿瘤坏死因子超家族受体9的特异性抗原结合蛋白及其应用
WO2025217398A1 (en) 2024-04-10 2025-10-16 Lyell Immunopharma, Inc. Methods for culturing cells with improved culture medium
CN118930648B (zh) * 2024-08-22 2025-02-28 武汉爱博泰克生物科技有限公司 抗人pax8蛋白的兔单克隆抗体、抗体偶联物及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US7651686B2 (en) 2001-10-09 2010-01-26 Mayo Foundation For Medical Education And Research Enhancement of immune responses by 4-1bb-binding agents
AR046094A1 (es) * 2003-10-10 2005-11-23 Bristol Myers Squibb Co Anticuerpos completamente humanos contra 4-1bb humano
US20080152655A1 (en) * 2004-09-08 2008-06-26 The Ohio State University Research Foundation Combination Therapy With Anti-Ctla4 and Anti-4-1BB Antibodies
AU2015252014B2 (en) * 2009-04-23 2017-03-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human ror1 antibodies
MX337040B (es) * 2010-09-09 2016-02-09 Pfizer Moleculas de union a 4-1bb.
ES2657970T3 (es) * 2010-12-01 2018-03-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anticuerpos contra ROR1 de conejo/ser humano quiméricos
GB201020995D0 (en) * 2010-12-10 2011-01-26 Bioinvent Int Ab Biological materials and uses thereof
EP3604339B1 (en) * 2011-01-14 2021-03-10 The Regents Of The University Of California Therapeutic antibodies against ror-1 protein and methods for use of same
KR101764096B1 (ko) * 2011-11-28 2017-08-02 메르크 파텐트 게엠베하 항-pd-l1 항체 및 그의 용도
ES2702315T3 (es) * 2012-08-24 2019-02-28 Univ California Anticuerpos y vacunas para su uso en tratar cánceres ROR1 e inhibir metástasis
CA2935748A1 (en) * 2014-02-25 2015-09-03 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
CA3138083A1 (en) * 2014-12-22 2016-06-30 Systimmune, Inc. Bispecific tetravalent antibodies and methods of making and using thereof
CN104817642B (zh) * 2015-05-04 2018-03-27 北京百普赛斯生物科技有限公司 抗人ror1单克隆抗体及其制备方法与应用
SG11202008474QA (en) * 2018-03-27 2020-10-29 Systimmune Inc Guidance and navigation control proteins and method of making and using thereof

Similar Documents

Publication Publication Date Title
JP2020529863A5 (enExample)
JP2020529862A5 (enExample)
JP7464764B2 (ja) 抗ror1抗体とその作製及び使用方法
JP2020531043A5 (enExample)
JP7685095B2 (ja) 多重特異性抗体とその作製及び使用方法
IL276830B2 (en) Anti-claudin 18.2 antibodies and uses thereof
JP2024037894A5 (enExample)
JP2020530776A5 (enExample)
JP2021515559A5 (enExample)
JP2023509196A5 (enExample)
JP7399852B2 (ja) 多重特異性抗体とその作製及び使用方法
RU2008135132A (ru) Антитела-антагонисты интерлейкина-17 (ил-17) для лечения рака
JP2024527606A5 (enExample)
JP2020528750A5 (enExample)
RU2014101669A (ru) Агенты, связывающие белки r-спондины (rspo), и способы их применения
JP2022533418A5 (enExample)
TW202537975A (zh) 抗體-藥物結合物之製造方法
JP2020502271A5 (enExample)
JP2020501531A5 (enExample)
FI3218005T3 (fi) Glykaanin kanssa vuorovaikutteisia yhdisteitä ja käyttömenetelmiä
FI3452513T3 (fi) Humanisoituja anti-il-1r3-vasta-aineita
RU2016147206A (ru) Полипептиды и полинуклеотиды и их применение для лечения иммунологических нарушений и рака
RU2017114968A (ru) Связывающие молекулы, а именно антитела, способные связываться с l1cam (cd171)
JP2022526841A5 (enExample)
JP2021501575A5 (enExample)